These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17060595)

  • 1. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
    Spanaki C; Latsoudis H; Plaitakis A
    Neurology; 2006 Oct; 67(8):1518-9. PubMed ID: 17060595
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.
    Madzar D; Schulte C; Gasser T
    Eur J Neurol; 2009 Nov; 16(11):1230-2. PubMed ID: 19538213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lrrk2 R1441 substitution and progressive supranuclear palsy.
    Ross OA; Whittle AJ; Cobb SA; Hulihan MM; Lincoln SJ; Toft M; Farrer MJ; Dickson DW
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):23-5. PubMed ID: 16409550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel LRRK2 mutations in Parkinsonism.
    Trinh J; Guella I; McKenzie M; Gustavsson EK; Szu-Tu C; Petersen MS; Rajput A; Rajput AH; McKeown M; Jeon BS; Aasly JO; Bardien S; Farrer MJ
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1119-21. PubMed ID: 26213354
    [No Abstract]   [Full Text] [Related]  

  • 7. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.
    Nichols WC; Elsaesser VE; Pankratz N; Pauciulo MW; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T;
    Neurology; 2007 Oct; 69(18):1737-44. PubMed ID: 17804834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.
    Zabetian CP; Samii A; Mosley AD; Roberts JW; Leis BC; Yearout D; Raskind WH; Griffith A
    Neurology; 2005 Sep; 65(5):741-4. PubMed ID: 16157909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
    Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
    Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
    Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred.
    Gosal D; Lynch T; Ross OA; Haugarvoll K; Farrer MJ; Gibson JM
    Mov Disord; 2007 Jan; 22(2):291-2. PubMed ID: 17089395
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.